Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Lloyds director makes share purchase

Thu 01 Dec 2022 15:19

(Sharecast News) - Lloyds Banking Group revealed on Thursday that non-executive director Cathy Turner had acquired 424,113 ordinary shares in the FTSE 100-listed retail banking company. Turner, who joined Lloyds' board on 1 November, purchased the shares on Wednesday at an average price of 46.92p each, for a total value of £198,993.81.

Back in October, Lloyds lifted net interest margin guidance despite a fall in third-quarter profit and a rise in bad loan charges as the economic crisis started to worsen.

Pre-tax profit fell 26% to £1.5bn, while net income rose 12% to £13.0bn on the back of surging interest rates with impairment charges soaring to £668.0m from a release of £119.0m a year ago.

As of 1605 GMT, Lloyds shares were down 1.11% at 46.38p each.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Thu 03 Sep 2026 15:14
Director dealings: Eurocell chairman raises stake
(Sharecast News) - Eurocell revealed on Thursday that non-executive chairman Derek Mapp had acquired 21,325 ordinary shares in the London-listed building products manufacturer.
Wed 02 Sep 2026 12:54
Director dealings: Greatland Gold director lowers stake
(Sharecast News) - Greatland Gold revealed on Wednesday that non-executive director Alexander Borrelli had disposed of 526,880 ordinary shares in the AIM-listed gold and copper miner.
Tue 01 Sep 2026 12:14
Director dealings: Genedrive CEO raises stake
(Sharecast News) - Genedrive revealed on Tuesday that chief executive Gino Miele had acquired 700,000 ordinary shares in the AIM-listed pharmacogenetic testing company.
Fri 28 Aug 2026 13:15
Director dealings: Watkin Jones chairman raises shareholding
(Sharecast News) - Watkin Jones revealed on Friday that non-executive chair Alan Giddins had acquired 50,000 ordinary shares in the AIM-listed developer.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026